Drug
Resten MP
Resten MP: highest development phase Phase 2, developed by Sarepta Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| RESTEN-MP NCT00248066 | Phase 2 | Coronary Artery Disease |
| RESTEN-MP NCT00244647 | Phase 1 | Coronary Artery Disease |
Latest
No recent events.
Follow Resten MP on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.